|
EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
{contributors}
|
To view the clinical trial data of the following topics click
here (pdf format)
Hepatocellular
cancer
Jennifer Knox, MSc, MD, FRCPC
SORAFENIB IMPROVES SURVIVAL IN ADVANCED HEPATOCELLULAR CARCINOMA
(HCC): RESULTS OF A PHASE III RANDOMIZED PLACEBO-CONTROLLED
TRIAL (SHARP TRIAL). ASCO 2007, ABSTRACT LBA 1.
Resectable
liver metastases in colorectal cancer
Hagen Kennecke, MD, MHA , FRCPC
FINAL RESULTS OF THE EORTC INTERGROUP RANDOMIZED PHASE III
STUDY 40983 [EPOC ] EVALUATING THE BENEFIT OF PERI-OPERATIVE
FOLFOX 4 CHEMOTHERAPY FOR PATIENTS WITH POTENTIALLY RESECTABLE
COLORECTAL CANCER LIVER METASTASES. ASCO 2007, ABSTRACT LBA
5.
Small
cell lung cancer
by Cheryl Ho, MD, FRCPC
A RANDOMIZED TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION (PCI)
VERSUS NO PCI IN EXTENSIVE DISEASE SMALL CELL LUNG CANCER
AFTER A RESPONSE TO CHEMOTHERAPY (EORTC 08993-22993). ASCO
2007, ABSTRACT 4.
Non-squamous
non-small cell lung cancer
Janessa Laskin, MD, FRCPC
RANDOMISED, DOUBLE-BLIND MULTICENTRE PHASE III STUDY OF BEVACIZUMAB
IN COMBINATION WITH CISPLATIN AND GEMCITABINE IN CHEMOTHERAPY-NAÏVE
PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL
CELL LUNG CANCER (NSCLC): BO17704. ASCO 2007, ABSTRACT LBA7514.
Non-small
cell lung cancer
Nevin Murray, MD, FRCPC
PHASE III TRIAL OF CISPLATIN (P) PLUS ETOPOSIDE (E) PLUS CONCURRENT
CHEST RADIATION (XRT) WITH OR WITHOUT CONSOLIDATION DOCETAXEL
(D) IN PATIENTS (PTS) WITH INOPERABLE STAGE III NON-SMALL
CELL LUNG CANCER (NSCLC): HOG LUN 01-24/USO-023. ASCO 2007,
ABSTRACT 7512.
Melanoma
Teresa Petrella, BSc, MD, MSc,
FRCPC
EORTC 18991: LONG-TERM ADJUVANT PEGYLATED INTERFERON-ALPHA2B
(PEG-IFN) COMPARED TO OBSERVATION IN RESECTED STAGE III MELANOMA,
FINAL RESULTS OF A RANDOMIZED PHASE III TRIAL.
Trastuzumab
in breast cancer
Joseph Ragaz, MD, FRCPC
UPDATED RESULTS OF THE COMBINED ANALYSIS OF NCCTG N9831 AND
NSABP B-31 ADJUVANT CHEMOTHERAPY WITH/WITHOUT TRASTUZUMAB
IN PATIENTS WITH HER2-POSITIVE BREAST CANCER. ASCO 2007, ABSTRACT
512.
BENEFIT FROM ADJUVANT TRASTUZUMAB MAY
NOT BE CONFINED TO PATIENTS WITH IHC 3+ AND/OR FISH-POSITIVE
TUMORS: CENTRAL TESTING RESULTS FROM NSABP B-31. ASCO 2007,
ABSTRACT 511.
To view the clinical trial data click
here (pdf format)
|
